LOCAMETZ allows visualization of PSMA+ metastases—regardless of location—in accordance with established guidelines[1,2]

LOCAMETZ®
Kit for the preparation of gallium Ga 68 gozetotide
INJECTION FOR INTRAVENOUS USE

How to acquire images using LOCAMETZ® (kit for the preparation of gallium Ga 68 gozetotide injection)[1]

1. PREPARE AND ADMINISTER LOCAMETZ	Follow the recommended dosing and administration instructions in the full Prescribing Information
2. ALLOW FOR REQUIRED UPTAKE TIME	Acquire PET images 50 to 100 minutes after the intravenous administration of LOCAMETZ
3. ACQUIRE THE IMAGE	Scan the whole body, starting at mid-thigh and proceeding to skull base or skull vertex
4. OPTIMIZE AS NEEDED	Adapt imaging technique according to the equipment used and patient characteristics

Indication

LOCAMETZ® (kit for the preparation of gallium Ga 68 gozetotide injection), after radiolabeling with gallium-68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer:

- with suspected metastasis who are candidates for initial definitive therapy
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
- for selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products.

IMPORTANT SAFETY INFORMATION

Risk for Misinterpretation

Image interpretation errors can occur with LOCAMETZ PET. Negative imaging does not rule out the presence of prostate cancer and a positive imaging does not confirm the presence of prostate cancer. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as nonmalignant processes. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.

The performance of LOCAMETZ seems to be affected by serum PSA levels and by site of disease for imaging of biochemically recurrent prostate cancer, and by Gleason score for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy.

Please see additional Important Safety Information on the reverse and full Prescribing Information.

Recommendations for interpreting images made using LOCAMETZ follow current national and international guidelines[1,2]

- LOCAMETZ binds to PSMA. Based on the intensity of the signals, PSMA PET images obtained with gallium Ga 68 gozetotide indicate the presence of PSMA protein in tissue[1]
- Descriptions of location, extent, and intensity of PSMA ligand uptake are addressed in the most current SNMMI and EANM guidelines on prostate cancer imaging with gallium Ga 68 gozetotide[2]
- Image interpretation errors can occur with LOCAMETZ PET. Read more on the **Risk for Misinterpretation** warning within the Important Safety Information beginning on page 1

EANM, European Association of Nuclear Medicine; PSMA–, PSMA negative; PSMA+, PSMA positive; SNMMI, Society of Nuclear Medicine and Molecular Imaging.

References: 1. Locametz. Prescribing information. Novartis Pharmaceuticals Corp. **2.** Fendler WP, Eber M, Beheshti M, et al. ^{68}Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. *Eur J Nucl Med Mol Imaging*. 2017;44(6):1014-1024. doi:10.1007/s00259-017-3670-z

To learn more about LOCAMETZ, please visit LOCAMETZ-hcp.com.

IMPORTANT SAFETY INFORMATION (continued)

Radiation Risk

Gallium Ga 68 gozetotide contributes to a patient's long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to the patient and health care workers. Advise patients to be well hydrated prior to gallium Ga 68 gozetotide administration and to void immediately prior to and frequently during the first hours after image acquisition to reduce radiation exposure.

Adverse Reactions

Adverse reactions ≥0.5% in the VISION study were fatigue (1.2%), nausea (0.8%), constipation (0.5%), and vomiting (0.5%). Adverse reactions occurring at a rate of <0.5% were diarrhea, dry mouth, injection site reactions, and chills.

Please see full Prescribing Information.

NOVARTIS

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

4/25 FA-11395956